Advertisement

A gene expression classification test developed by San Fransisco-based Veracyte Inc., and being co-marketed by Genzyme, a Sanofi company, helps reduce unnecessary surgery in patients at risk for thyroid cancer, according to a study published by the journal, Thyroid.

Advertisement
Advertisement